Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study.
نویسندگان
چکیده
The PROLONG randomized trial showed that a normal D-dimer (D-d) 1 month after anticoagulation suspension for unprovoked venous thromboembolism (VTE) was associated with a low risk of late recurrences (4.4% patient years). However, it is unknown whether D-d changes subsequently. The aim of this prospective multicenter study was to assess D-d time course and its relation with late recurrences in patients with normal D-d 1 month after anticoagulation suspension for a first episode of unprovoked VTE. D-d was measured with a qualitative method (Clearview Simplify D-dimer; Inverness Medical Professional Diagnostics). Patients with a normal D-d 1 month after stopping anticoagulation repeated D-d testing every 2 months for 1 year. D-d was normal in 68% (243/355) of patients 1 month after anticoagulation suspension. Patients in whom D-d became abnormal at the third month and remained abnormal afterward had a higher risk of recurrence (7/31; 27% patient years; 95% confidence interval [CI]: 12-48) than patients in whom D-d remained normal at the third month and afterward (4/149; 2.9% patient years; 95% CI: 1-7; adjusted hazard ratio: 7.9; 95% CI: 2.1-30; P = .002). Repeated D-d testing after anticoagulation suspension for a first episode of unprovoked VTE could help tailor the duration of treatment. This trial is registered at http://clinicaltrials.gov as NCT00266045.
منابع مشابه
Guided duration of anticoagulation after unprovoked venous thromboembolism using D-dimer testing.
Venous thromboembolism (VTE) is a frequent, multifactorial and potentially life-threatening disease [1–3]. When VTE occurs in the absence of any major risk factor (i.e. surgery, prolonged immobilisation or trauma of the lower limb), the risk of recurrent VTE is high (i.e. about 10% at 1 year and 30% at 5 years) after anticoagulation therapy is stopped, and current guidelines recommended indefin...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study
1Department of Angiology and Blood Coagulation, Marino Golinelli University Hospital St Orsola-Malpighi, Bologna; 2Department of Hematology, S Bortolo Hospital, Vicenza; 3Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova; 4Department of Internal Medicine I, Angiology, Arcispedale Santa Maria Nuova, Reggio Emilia; 5Haemostasis and Thrombosis ...
متن کاملSystematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
BACKGROUND The optimal duration of anticoagulation for a first episode of unprovoked venous thromboembolism (VTE) is uncertain. Methods for predicting risk for recurrence may identify low-risk patients who are less likely to benefit from prolonged anticoagulation. PURPOSE To synthesize evidence evaluating the value of D-dimer as a predictor of recurrent disease in patients who have stopped an...
متن کاملTrial Protocol: A randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study)
BACKGROUND Venous thromboembolism comprising pulmonary embolism and deep vein thrombosis is a common condition with an incidence of approximately 1 per 1,000 per annum causing both mortality and serious morbidity. The principal aim of treatment of a venous thromboembolism with heparin and warfarin is to prevent extension or recurrence of clot. However, the recurrence rate following a deep vein ...
متن کاملDuration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
It takes about 3 months to complete "active treatment" of venous thromboembolism (VTE), with further treatment serving to prevent new episodes of thrombosis ("pure secondary prevention"). Consequently, VTE should generally be treated for either 3 months or indefinitely (exceptions will be described in the text). The decision to stop anticoagulants at 3 months or to treat indefinitely is dominat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 115 3 شماره
صفحات -
تاریخ انتشار 2010